Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Science Translational Medicine | August 7, 2019 | Volume: 11 | Issue: 504 | Pages: No page available
10.1126/scitranslmed.aax7392
| PMID 31391323
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy.